Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses Chinese Rights to Liver Cancer Drug


Alnylam Pharmaceuticals said this week that it has licensed the Chinese rights to its RNAi-based liver cancer drug ALN-VSP to US/Chinese pharmaceutical firm Ascletis Pharmaceuticals.

The drug comprises siRNAs against two targets: vascular endothelial growth factor, which is associated with angiogenesis, and kinesin spindle protein, which has been linked to cell proliferation in various cancers. Although the agent offered some signs of efficacy in phase I testing, Alnylam previously said it would not advance it into phase II without a partner (GSN> 5/10/2012).

Under the terms of the new deal, Ascletis will have the exclusive rights to ALN-VSP in China, Hong Kong, Macau, and Taiwan. Alnylam retains the product rights in all other markets.

Ascletis aims to move the agent into a phase II trial, and Alnylam said it may use the data generated in this study for use in ALN-VSP programs in territories not included in the collaboration, should it secure the partnership it requires for the drug's continued development.

Alnylam stands to receive milestones and royalties from Ascletis. Additional terms of the deal were not disclosed.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.